THCjd

THCjd is a recently described tetrahydrocannabinol analog bearing an octyl (C8) alkyl side chain. It has appeared in commercial vape products marketed as an ultra-potent cannabinoid, but peer-reviewed characterization is extremely limited — a handful of analytical papers (e.g., from cannabis-testing groups in 2022–2024) confirm the structure, and vendor claims of "CB1 affinity higher than THCP" rest on extrapolated structure–activity relationships rather than published binding data. ⚠️ As of April 2026, no human pharmacokinetic or efficacy trials, no completed preclinical toxicology, and no authoritative receptor-binding measurements have been published. The compound is effectively a novel industrial product sold to consumers. Treat all potency and safety statements with strong caution; its legal status varies and is likely to be restricted alongside other semi-synthetic hemp derivatives. → See also: THCP, Synthetic cannabinoid, Minor cannabinoid.